Lead Product(s): Prasinezumab
Therapeutic Area: Neurology Product Name: PRX002
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 10, 2021
Company has earned a $60 million milestone from its worldwide collaboration with Roche based on the first patient dosed in the Phase 2b PADOVA study of prasinezumab in patients with early Parkinson's disease.
Lead Product(s): Ropivacaine Hydrochloride
Therapeutic Area: Neurology Product Name: PRF-110
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2021
PRF-110 is based on the local anesthetic ropivacaine, targeting post-operative pain relief market. PRF-110 is an oil-based, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia.